Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study
Brian Bressler*, Andres Yarur, Mark S. Silverberg, Marielle Bassel, Emanuelle Bellaguarda, Chris Fourment, Anthie Gatopoulou, Pantelis Karatzas, Uri Kopylov, George Michalopoulos, Spyridon Michopoulos, Udayakumar Navaneethan, David T. Rubin, Jesse Siffledeen, Andrew Singh, Konstantinos Soufleris, Dara Stein, Dirk Demuth, Gerassimos J. Mantzaris
Dive into the research topics of 'Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study'. Together they form a unique fingerprint.